ADA: Hengrui, Innovent’s Incretins Shine In China Obesity Studies

Potential Comparative Advantages?

 
• By Dexter Jie Yan
  
China obesity market
Hengrui and Innovent presented latest clinical results for their respective dual incretin receptor agonists at ADA annual meeting. • Source: Shutterstock

More from China

More from Focus On Asia